Comparison of the Efficacy of EGFR-TKIs Combined with Antiangiogenic Agents between Patients with Exon 19 Deletion and Patients with Exon 21 Leu858 Arg Mutation: A Systematic Review and Meta-Analysis

<div>Forest plot of the hazard ratio of the progression-free survival of exon 19 deletion receiving EGFR-TKIs plus antiangiogenic agents and EGFR-TKIs. HR: hazard ratio; CI: confidence interval.</div>

Journal of Oncology

fig3

Figure 3

Figure 3: Comparison of the Efficacy of EGFR-TKIs Combined with Antiangiogenic Agents between Patients with Exon 19 Deletion and Patients with Exon 21 Leu858 Arg Mutation: A Systematic Review and Meta-Analysis 

Figure 3 | Comparison of the Efficacy of EGFR-TKIs Combined with Antiangiogenic Agents between Patients with Exon 19 Deletion and Patients with Exon 21 Leu858 Arg Mutation: A Systematic Review and Meta-Analysis 